a lot of 'baby' bios are getting hacked up. CRMD for example just rec'd FDA approval of a compound that WILL become the standard of care because of its effectiveness. And despite the news, since the 'launch' isn't till (later?) in the 1st qtr 2024, its gone 'no where' on the news.
ATNM has gotten clocked, but what the heck, given a target price of $20+ (if they would stop selling frigging shares), its a 'gift' at these prices. But like CRMD, its going to have to EXECUTE (get approved and get sales going).
Got 1 other that has very good potential, but again, folks just don't seem to be interested in something that isn't 'doing'
I was just browsing thru their website, going over their Nov presentation. Was looking for an update on the BLA filing, see someone posted its now into the 1H 2024. Was going to start accumulating, but a look at the chart is indicating $4 may not hold now. So going to continue to be patient. Cause I suspect given the early stages for the rest of their effort (and years to an endpoint), the only thing that might turn this around would be news of the filing. And with that pushed back? LIke CRMD, the market is not being kind to baby bios. Course the other thing is, when the market turns from 'no price is too high' to lets get 'real''? Whats a 'fair value' takes on a whole different perspective. (example: Sava back when it was completing a PH 2 hit over $120/sh look at where its at now..and I would argue its still overvalued given what they have PROVEN)
Disclaimer: still being patient to buy back in.. And getting it down here just increases the potential reward if they can get approved)
Are you looking at another chart than me? On the six month chart the SP has been cut in half. The last pull was BLA filing being moved from H2 23 to H1 24.
Actinium Pharmaceuticals announced that it will be attending Bio-Europe, the
largest biopharmaceutical industry partnering event in Europe, taking place November 6 -- 8, 2023 in Munich, Germany.
Members of Actinium's senior leadership team will be available for one-on-one meetings during the in-person meeting as
well as the digital partnering taking place November 14-15, 2023. To request a meeting with Actinium through
partneringONE(R) https://informaconnect.com/bioeurope/. Interested parties may also contact the Company directly to
schedule in person or virtual meetings by emailing Actinium.
Actinium is advancing a pipeline of differentiated, clinical-stage targeted radiotherapeutics including Iomab-B for
bone marrow transplant conditioning, which met the primary endpoint in the Phase 3 SIERRA trial and is being prepared
for a BLA filing, Iomab-ACT for conditioning prior to cell and gene therapy and Actimab-A as a therapeutic for relapsed
or refractory acute myeloid leukemia that has shown backbone therapy potential in combinations. Actinium is also
advancing novel solid tumor programs leveraging its industry leading experience with the alpha-particle payload
Actinium-225 and intellectual property including linker technology and Actinium-225 manufacturing.
Don’t get me wrong. I still have faith in the science and want to believe the company will come through with the ultimate goal of submission and approval. These down days are difficult to take after an already long process. If I had some dry powder, I’d probably see it as an opportunity as well. Maybe I’m hoping for a glimmer of positivity that would help support the share price in the near term? Thanks for the encouraging example though.
But the opportunity to be taken advantage of.
Had another one CRMD get I suspect 'shorted' down heavily in the run up to its pending decision date (Nov 15th. Now at $3.3-3.4 range, target is still $14-15)..
Been watching ATNM and kind of wondering if it would get a similar share price hit.
And as far as I know, its still on track for an NDA submission before the end of the year?? So going to take advantage of this and start accumulating a position. And see it still has a target price of $27 making this price level or less, one heck of a buy given that their development 'appears/sounds' successful/approvable.
Disclaimer: own none at the moment, but going to after this takedown.
Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial
November 02 2023 - 09:05AM
PR Newswire (US)
Share On Facebook
- Relapsed or refractory AML patients with a TP53 mutation receiving Iomab-B led allogeneic bone marrow transplant had a median Overall Survival of 5.49 months compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002)
- Iomab-B's mutation-agnostic mechanism overcomes TP53 mutations and produced similar median Overall Survival outcomes of 6.37 months in TP53 negative patients and 5.72 months in TP53 positive patients
- Twenty-four percent of patients enrolled on SIERRA had a TP53 mutation that is typically associated with worse outcomes
- Oral presentation scheduled for Sunday, December 10, 2023, with two additional poster presentations detailing SIERRA trial results accepted for presentation
- Actinium reports third quarter financial results and provides a business update
NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that three abstracts detailing results from the completed Phase 3 SIERRA trial of Iomab-B in patients age 55 and above with active relapsed or refractory acute myeloid leukemia (r/r AML) have been accepted for presentation at the 65th Annual American Society of Hematology Annual Meeting & Exposition (ASH) being held in San Diego on December 9-12, 2023. Outcomes of patients with a TP53 gene mutation enrolled in the SIERRA trial have been accepted for an oral presentation and results detailed in the abstract include the following:
(PRNewsfoto/Actinium Pharmaceuticals, Inc.)
Median Overall Survival (OS) of TP53 positive patients receiving Iomab-B and a bone marrow transplant (BMT) was 5.49 months compared to 1.66 months in patients who did not receive Iomab-B
Iomab-B produced a statistically significant improvement in median OS in TP53 positive patients with a hazard ratio of 0.23 and p-value of 0.0002
Median OS of 6.37 months in TP53 negative patients receiving Iomab-B and 5.72 months for TP53 positive patients demonstrating Iomab-B's mutation agnostic mechanism and ability to overcome TP53 gene mutations
24% of patients (37/153) enrolled on the SIERRA trial had a TP53 mutation, with 17 being randomized to the Iomab-B arm and 20 randomized to the control arm
Dr. Avinash Desai, Actinium's Chief Medical Officer, commented, "We are very excited by these results which show a statistically significant and greater than three-times increase in median OS in TP53 positive patients receiving Iomab-B. These results further support Iomab-B's differentiated profile and ability to improve outcomes for the most difficult to treat r/r AML patients. A TP53 gene mutation is arguably the most unfavorable risk factor leading to the worst patient outcomes as it is associated with inherent resistance to available therapies, short duration of responses and the lowest survival rates. Despite being a common mutation found in approximately 10-15% of all AML cases and up to 25% of patients over age 60, there are no approved therapies that target TP53. For patients with high-risk AML, particularly those with r/r disease and a TP53 mutation, BMT is associated with the best treatment outcomes and is the only potentially curative therapeutic option. Iomab-B's ability to facilitate a BMT in this patient population continues to demonstrate a strong clinical benefit as supported by these results and we look forward to presenting the full TP53 analysis at ASH in early December."
Detailed results will be presented in an oral presentation on December 10, 2023, as follows:
Session Name: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Novel Conditioning Regimens for Myeloid Malignancies
Session Date: Sunday, December 10, 2023
Session Time: 9:30 AM - 11:00 AM Pacific Time
Presentation Time: 9:30 AM
Room: Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19
Publication Number: 469
Title: 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML
Submission ID: 182177
Iomab-B is a new type of treatment for patients with relapsed or refractory acute myeloid leukemia (r/r AML), a type of blood cancer that is difficult to treat and has a poor prognosis.
Iomab-B is a targeted radiotherapy that uses a monoclonal antibody to deliver radiation directly to the bone marrow and spleen, where most of the leukemia cells are located.
This way, Iomab-B can destroy the cancer cells and prepare the patient for a bone marrow transplant (BMT), which is a potentially curative procedure.
Iomab-B has been tested in a large clinical trial called SIERRA, which showed positive results for patients who received Iomab-B and BMT compared to those who received conventional chemotherapy and BMT.
Some of the key findings from the SIERRA trial are:
• All patients who received Iomab-B were able to access BMT, while only 17% of patients who received chemotherapy were able to do so1.
• Patients who received Iomab-B had a higher rate of remission after BMT than those who received chemotherapy (75% vs 6.3%)1.
• Patients who received Iomab-B had a longer median overall survival than those who received chemotherapy (6.37 months vs 1.66 months)2.
• Patients who had a TP53 gene mutation, which is associated with worse outcomes in AML, had a similar median overall survival as those who did not have the mutation when they received Iomab-B (5.72 months vs 6.37 months)2.
• Iomab-B was well tolerated and had manageable side effects1.
Iomab-B is a promising new therapy for r/r AML patients who need a BMT but cannot achieve remission with conventional chemotherapy.
It is currently under review by the FDA for approval3.
If you want to learn more about Iomab-B, you can visit the official website of the SIERRA trial4 or the website of Actinium Pharmaceuticals, the company that developed Iomab-B1.
Part of me agrees that the FDA is already in the big pharma’s back pocket. A greater part of me thinks in ATNM’s case at least, the delay may be more due to 1. The limited resources the company has to provide a viable NDA. 2. The impact of ATNM’s treatment vs. say the COVID vaccine in terms of patients served.
I am starting to wonder if the 'length' of time to get something approved is relational to whether its a 'baby bio' vs one of the big pharma - fda 'revolving' door companies up for approval.
And yeah, the covid scam/hoax demonstrated how things 'really' work when 'something' is 'desired' didn't it.
Found this on stocktwits
For those wondering what’s going on behind the scenes. Iomab-B, $ATNM lead PHIII complete cancer treatment, is being presented to the Department of Health & Human Services Centers for Medicare & Medicaid Services on September 12, 2023 for the determination of Iomab-B ICD-10 codes. Used for medical claim reporting in all healthcare settings, ICD-10 codes are the primary means to establish medical necessity for payment of healthcare services and procedures.
April 2024 implementation.
It doesn’t look like they are covering these NTAPS on the zoom
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850 CENTER FOR MEDICARE ICD-10 Coordination and Maintenance Committee Meeting ICD-10-PCS Therapeutic Agent Topics Consistent with the requirements of section 1886(d)(5)(K)(iii) of the Social Security Act, applicants submitted requests to create a unique procedure code to describe the administration of a therapeutic agent, such as the option to create a new code in Section X within the International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS). CMS is soliciting public comments on the proposed coding options and any clinical questions for two procedure code topics associated with new technology add-on payment (NTAP)-related ICD-10- PCS procedure code requests that involve the administration of a therapeutic agent. The deadline to submit comments for these topics being considered for an April 1, 2024 implementation is October 13, 2023. Members of the public should send any questions or comments to the CMS mailbox at: ICDProcedureCodeRequest@cms.hhs.gov. Prior to the meeting, CMS will post a question and answer document on our website at https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials to address clinical or coding questions that members of the public have submitted related to the two therapeutic agents, as discussed in the following pages. At a later date, CMS will post an updated question and answer document to address any additional clinical or coding questions that members of the public may have submitted by the October 13, 2023 deadline. CMS will not be presenting the NTAP-related ICD-10-PCS procedure code requests that involve the administration of a therapeutic agent at the September 12, 2023 virtual meeting. CMS will present the NTAP-related ICD-10-PCS procedure code requests that do not involve the administration of a therapeutic agent and all non-NTAP-related procedure code requests during the virtual meeting on September 12, 2023. Comments on all procedure code proposals should be sent to the following email address: ICDProcedureCodeRequest@cms.hhs.gov.
Looking for info on the above I got this from ai chat
I’m sorry, but I couldn’t find any specific information about the presentation of Iomab-B’s Phase III complete cancer treatment to the Department of Health & Human Services Centers for Medicare & Medicaid Services on September 12, 2023, for the determination of Iomab-B ICD-10 codes. However, I can share that Iomab-B is a first-in-class targeted radiotherapy developed by Actinium Pharmaceuticals1. It has shown positive results in the pivotal Phase 3 SIERRA Trial for patients with active relapsed or refractory Acute Myeloid Leukemia32. The trial met its primary endpoint of durable complete remission of 6-months following initial complete remission after Hematopoietic Cell Transplantation (HCT) with a p-value of <0.000132. For more specific information regarding the presentation and ICD-10 codes, I would recommend reaching out to the relevant health authorities or Actinium Pharmaceuticals directly.
My bet is they do but my time horizon is longer if they don’t make year’s end.
So many of these biotechs are taking “far longer than expected”. I’ve been waiting on NWBO forever (and still believe I will eventually come out with at least a 10 bagger upon approval). I hope your Cormedix bears fruit soon but I’m quickly finding out that unless you have the metaphorical “cure for COVID”, nothing happens quickly in the world of biotech!
agree. Just that I am 'all in' on CRMD and its pending Nov 15th date with the FDA.. Looking for $12 to $15 on that one for starters. Damn delays in its approval have cost me 'opportunities' on another one as I have had to 'wait'... far longer than expected over 2 years ago.. And now a bargain on ATNM
Be nice to roll some of that one into some shares sub $8 on this one..
Just bought a little more to add to my small position as this is too tempting an opportunity.
Been a while, but have been monitoring the share price trend. Also tracking the FLOAT, hope they can keep it sub 30 Mil shares (26 Mil) so that the darn 'target price' doesn't get hit like it has for one I am heavily in at the moment (delays in their approval timeline has forced ATM dilution).
And know this won't be a likeable comment, but if it can hold sub $8 into the end of the year?? With a target price of around $25-30?? Be a happy buyer for the run into their approval decision (question is, are they still on track for an NDA submission late this year??)
disclaimer: currently own none, but am bullish especially as the price has slid lower
@4 follow for you , PLEASE hit me back
Sorry, not sure what you’re asking. Actinium as a radioactive atom doesn’t exist naturally and is extremely rare. That being said, the company, Actinium pharmaceuticals, uses radioactive elements combined with human antibodies to fight blood cancers.
How valuable is raw ACTINIUM I have #11 pounds?~~~~from one of my gold mines in ALASKA.
There are signals in the stock today. The Actinium Pharmaceuticals, Inc stock holds signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $7.07 and $7.48. A break-up above any of these levels will issue buy signals. A buy signal was issued from a pivot bottom point on Thursday, July 27, 2023, and so far it has risen 0.579%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price.
This is considered to be a good technical signal.
NEW YORK, July 24, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company will participate in the 2nd Annual Targeted Radiopharmaceuticals Summit in Boston, July 25 - 27, 2023. Actinium will present "Targeted Radiotherapeutics & Innovative Combinations to Alter the Treatment Outcome for Conditioning, Hematological & Solid Tumor Malignancies" on Thursday, July 27, 2023 at 12:30pm ET.
After my sale last year, I’ve determined that my time horizon for this stock is a lot longer and also depends on how much the price will increase after an FDA approval.
Actinium Pharmaceuticals ATNM Stock Price Target $33.25
52 Week high $15.12
The Short interest report
Last report 6/30/2023
8.7 Dayd to Cover
Forecast is for Shorts to Cover
Actinium Pharmaceuticals Inc Stock Price Forecast for 2023
August 2023 7.289 8.189 7.289 8.21310.99 % ?
September 2023 8.162 8.852 8.162 8.8637.8 % ?
October 2023 8.892 9.328 8.833 9.3284.68 % ?
November 2023 9.351 9.244 9.244 9.466-1.16 %?
December 2023 9.221 9.193 9.193 9.325-0.3 %?
Actinium Pharmaceuticals Inc Stock Price Forecast for 2024
January 2024 9.177 9.179 9.026 9.1880.01 % ?
February 2024 9.180 8.862 8.862 9.251-3.59 %?
March 2024 8.828 9.701 8.828 9.7048.99 % ?
April 2024 9.768 9.714 9.710 9.829-0.55 %?
May 2024 9.688 9.761 9.446 9.7660.75 % ?
June 2024 9.820 9.209 9.209 9.847-6.63 %?
July 2024 9.213 9.349 9.201 9.3491.46 % ?
August 2024 9.369 10.239 9.369 10.2908.5 % ?
September 2024 10.254 10.962 10.254 10.9626.45 % ?
October 2024 10.989 11.406 10.907 11.4063.66 % ?
November 2024 11.409 11.293 11.293 11.532-1.02 %?
December 2024 11.321 11.278 11.267 11.404-0.38 %?
Actinium Pharmaceuticals Inc Stock Price Forecast for 2025
January 2025 11.259 11.226 11.099 11.259-0.29 %?
February 2025 11.283 10.915 10.915 11.319-3.38 %?
March 2025 10.917 11.825 10.917 11.8257.68 % ?
April 2025 11.862 11.787 11.787 11.903-0.64 %?
May 2025 11.756 11.810 11.512 11.8120.46 % ?
June 2025 11.882 11.291 11.291 11.915-5.24 %?
July 2025 11.311 11.404 11.270 11.4040.82 % ?
August 2025 11.410 12.318 11.410 12.3647.37 % ?
September 2025 12.329 13.057 12.320 13.0575.58 % ?
October 2025 13.056 13.449 12.985 13.4492.92 % ?
November 2025 13.544 13.369 13.369 13.613-1.31 %?
December 2025 13.391 13.349 13.349 13.480-0.31 %?
Actinium Pharmaceuticals Inc Stock Price Forecast for 2026
January 2026 13.325 13.284 13.174 13.325-0.31 %?
February 2026 13.343 13.007 13.007 13.403-2.59 %?
March 2026 12.994 13.919 12.993 13.9196.64 % ?
April 2026 13.927 13.854 13.854 13.978-0.53 %?
May 2026 13.810 13.855 13.584 13.8550.33 % ?
June 2026 13.939 13.389 13.373 13.981-4.1 %?
July 2026 13.379 13.446 13.341 13.4460.5 % ?
August 2026 13.569 14.407 13.569 14.4355.82 % ?
September 2026 14.427 15.124 14.386 15.1244.61 % ?
October 2026 15.117 15.485 15.065 15.4852.37 % ?
November 2026 15.590 15.462 15.447 15.694-0.83 %?
December 2026 15.487 15.414 15.414 15.555-0.47 %?
Actinium Pharmaceuticals Inc Stock Price Forecast for 2027
January 2027 15.377 15.341 15.251 15.377-0.24 %?
February 2027 15.402 15.104 15.104 15.482-1.97 %?
March 2027 15.078 15.983 15.053 15.9835.66 % ?
April 2027 15.986 15.908 15.908 16.052-0.49 %?
May 2027 15.869 15.990 15.661 15.9900.76 % ?
June 2027 16.032 15.459 15.459 16.052-3.71 %?
July 2027 15.442 15.489 15.415 15.4930.3 % ?
August 2027 15.596 16.505 15.596 16.5055.51 % ?
September 2027 16.496 17.184 16.457 17.1864.01 % ?
October 2027 17.166 17.518 17.140 17.5182.01 % ?
November 2027 17.632 17.559 17.528 17.771-0.41 %?
December 2027 17.554 17.467 17.467 17.628-0.5 %?
Actinium Pharmaceuticals Inc Stock Price Forecast for 2028
January 2028 17.451 17.459 17.330 17.4620.05 % ?
February 2028 17.496 17.178 17.168 17.556-1.85 %?
March 2028 17.162 18.032 17.121 18.0414.82 % ?
April 2028 18.083 18.003 18.003 18.126-0.45 %?
May 2028 17.969 18.095 17.744 18.0950.7 % ?
June 2028 18.100 17.493 17.493 18.139-3.47 %?
July 2028 17.511 17.523 17.507 17.5650.07 % ?
Congratulations on your treatment success! I also share your enthusiasm with ATNM but had substantially reduced my investment about a year ago. (Needed some cash). I still feel that what I have remaining will yield a solid return. Good luck with your continuing good health and your investments.
I am in ATNM Actinium Pharmaceuticals because it is a biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients.
I really do not care if i make or lose money on this stock.
I’d rather make money on my investment.
As a cancer survivor i would love to see more cancer companies with promising treatments.
ATNM will be back over the 52 week high.
Thanks to cancer treatments i will be hear to see another 52 week high.
My treatments were not a result of Actinium but radiation ?? treatment did kill my cancer.
ATNM broke over $14.50 twice in the last year.
The time to get in and hold while the price is low and hope for a run over $14 again.
I had hope and i keep that hope for ATNM
I added to my position Friday. I am in ATNM because i believe they can help people with cancer.
This is something you don’t think of until you have cancer yourself. Cancer treatments are not cheap.
Good thing for insurance.
Fact is Cancer sometimes can be beat.
Cancer will always be out there.
People will need cancer treatments.
Well time for me to get ready to drive to Orlando hospital for an injection, and again tomorrow for a pill to swallow and again Thursday for a scan to see if my treatment has worked.
My treatment is not related with any of ATNM trials or products. I just like what i see with ATNM
law of averages
Street target price: Avg based on yahoos finance page is $31/sh...
Something to track although they say they have a lot of cash on hand (they should they doubled up the damn share count to 25 Million) is the 'share count' which as of the end of the 1st qtr 2023 is around 25 Million..
So from a timeline standpoint, end of this year for an NDA submission.. add 9 months to that..
If I had shares right now, I would be selling the covered calls for what I could get, at the $10 level. Just don't see a reason coming in the near future to jeopardize $10/sh..
disclaimer: still don't have any, loaded with CRMD which just got their timeline clarified, sitting at $5/sh, target price $15 on 41 Million shares outstanding. And if they get the additional sector (oncology) we know they will be asking approval for, well that puts the target price north around $25+.. Just going to take till the end of the year for an FDA decision from the looks of it.
Been watching the share price and have to say, its gotten 'attractive' again at sub $10/sh..
See that they intend to file their NDA later this year, so given the time after that for a decision (around 9 months after the NDA is accepted),
Guess I will be looking to take another 'round' with this one..
and agree, unless the fed death agency screws around with them, the data indicates is should be approvable.
disclaimer: own none, but will be looking to accumulate.. Good luck.. at least there is a timeline now..
Results were definitely FDA approvable. Everyone is probably just upset because no buy out was announced. Give it time, it’ll bounce back.